Cohort Study of Pioglitazone and Bladder Cancer in Patients with Type II Diabetes

Documents

Study protocol

Study results

Study report

Study report

01-03-TL-OPI-524 10-Year Final Report

01-03-TL-OPI-524 8-year Interim Report

01-03-TL-OPI-524-4th_Interim_Report_(Additional_Sensitivity_Analysis)

01-03-TL-OPI-524-Proteinuria Analysis

Other information

Study, other information

01-03-TL-OPI-524 8-year Interim Report.pdf

01-03-TL-OPI-524-4th_Interim_Report_(Additional_Sensitivity_Analysis).pdf

01-03-TL-OPI-524-Proteinuria Analysis.pdf

Publications

Study publications

Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder…

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn …

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Composition of steering group and observers

Steering Group